Cargando…

Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability

OBJECTIVE: To describe patient preferences in selecting specific biologics and compare clinical response using patient reported outcomes (PROs) among patients with rheumatoid arthritis (RA) started on different anti-tumor necrosis factor (TNF) therapies. METHODS: Participants were enrollees in Kaise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Navarro-Millán, Iris, Herrinton, Lisa J., Chen, Lang, Harrold, Leslie, Liu, Liyan, Curtis, Jeffrey R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805235/ https://www.ncbi.nlm.nih.gov/pubmed/27007811 http://dx.doi.org/10.1371/journal.pone.0149781

Ejemplares similares

Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept
por: Dervieux, Thierry, et al.
Publicado: (2019)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
por: Dehoratius, Raphael J., et al.
Publicado: (2018)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
por: Chen, Hsin-Hua, et al.
Publicado: (2016)

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
por: Bonafede, Machaon, et al.
Publicado: (2013)

Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2012)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study
por: Larid, Guillaume, et al.
Publicado: (2022)

The use of Etanercept and Adalimumab in the management of JIA: a 5-year follow-up study
por: Trachana, M, et al.
Publicado: (2008)

Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis
por: Ruano, Juan, et al.
Publicado: (2013)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
por: Wcisło-Dziadecka, Dominika, et al.
Publicado: (2020)

Restoration of Default Blood Monocyte-Derived Macrophage Polarization With Adalimumab But Not Etanercept in Rheumatoid Arthritis
por: Paoletti, Audrey, et al.
Publicado: (2022)

Effects of Etanercept and Adalimumab on Serum Levels of Cartilage Remodeling Markers in Women with Rheumatoid Arthritis
por: Szeremeta, Anna, et al.
Publicado: (2023)

Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
por: van Muijen, Marloes E., et al.
Publicado: (2021)

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
por: van der Schoot, L.S., et al.
Publicado: (2023)

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis
por: Liu, Jing, et al.
Publicado: (2016)

Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis
por: Tao, Weiyang, et al.
Publicado: (2020)

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022)

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
por: Doan, Quan V., et al.
Publicado: (2006)

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
por: Bessette, Louis, et al.
Publicado: (2017)

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
por: ATALAY, Selma, et al.
Publicado: (2021)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
por: Incerti, Devin, et al.
Publicado: (2020)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
por: Soubrier, Martin, et al.
Publicado: (2018)

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
por: van Herwaarden, Noortje, et al.
Publicado: (2015)

Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015
por: Matsui, Toshinobu, et al.
Publicado: (2017)

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
por: Horneff, Gerd, et al.
Publicado: (2016)

Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial
por: Wei, James Cheng-Chung, et al.
Publicado: (2020)

Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)
por: Williams, Nefyn H., et al.
Publicado: (2018)

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients
por: Ding, Xiaoliang, et al.
Publicado: (2020)

Optimal dose of etanercept in the treatment of rheumatoid arthritis
por: Curtis, Elizabeth Mary, et al.
Publicado: (2014)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
por: ATALAY, Selma, et al.
Publicado: (2020)

Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database
por: Harnett, James, et al.
Publicado: (2016)

Etanercept therapy in JIA: impact on the need for intra-articular steroid injections
por: Pain, CE, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ij4po39r822beh37ot7nr7ce00